JP7839803B2 - 治療レジメンで使用するためのｐｉ３ｋ－デルタ阻害剤 - Google Patents

治療レジメンで使用するためのｐｉ３ｋ－デルタ阻害剤

Info

Publication number
JP7839803B2
JP7839803B2 JP2023560623A JP2023560623A JP7839803B2 JP 7839803 B2 JP7839803 B2 JP 7839803B2 JP 2023560623 A JP2023560623 A JP 2023560623A JP 2023560623 A JP2023560623 A JP 2023560623A JP 7839803 B2 JP7839803 B2 JP 7839803B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
dose
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023560623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518685A (ja
JP2024518685A5 (https=
Inventor
キャサリン・ピカリング
ラース・ファン・デル・ヴィーン
マイケル・ラーン
レベカ・ソリーリャ
ゾーイ・ジョンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura SA
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura SA filed Critical Ionctura SA
Publication of JP2024518685A publication Critical patent/JP2024518685A/ja
Publication of JP2024518685A5 publication Critical patent/JP2024518685A5/ja
Application granted granted Critical
Publication of JP7839803B2 publication Critical patent/JP7839803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2023560623A 2021-03-29 2022-03-29 治療レジメンで使用するためのｐｉ３ｋ－デルタ阻害剤 Active JP7839803B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GB2104416.9 2021-03-29
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
GB2117511.2 2021-12-03
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (3)

Publication Number Publication Date
JP2024518685A JP2024518685A (ja) 2024-05-02
JP2024518685A5 JP2024518685A5 (https=) 2025-04-04
JP7839803B2 true JP7839803B2 (ja) 2026-04-02

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560623A Active JP7839803B2 (ja) 2021-03-29 2022-03-29 治療レジメンで使用するためのｐｉ３ｋ－デルタ阻害剤

Country Status (17)

Country Link
US (1) US12605389B2 (https=)
EP (1) EP4313058B1 (https=)
JP (1) JP7839803B2 (https=)
AU (1) AU2022251843B2 (https=)
CA (1) CA3212731A1 (https=)
DK (1) DK4313058T3 (https=)
ES (1) ES3031295T3 (https=)
FI (1) FI4313058T3 (https=)
HR (1) HRP20250516T1 (https=)
HU (1) HUE071610T2 (https=)
LT (1) LT4313058T (https=)
MX (1) MX2023011442A (https=)
PL (1) PL4313058T3 (https=)
PT (1) PT4313058T (https=)
RS (1) RS66754B1 (https=)
SI (1) SI4313058T1 (https=)
WO (1) WO2022207646A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
AU2024231699A1 (en) * 2023-03-03 2025-09-11 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058149A1 (en) 2009-11-13 2011-05-19 Merck Serono S.A. Tricyclic pyrazol amine derivatives
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058149A1 (en) 2009-11-13 2011-05-19 Merck Serono S.A. Tricyclic pyrazol amine derivatives
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms

Also Published As

Publication number Publication date
PT4313058T (pt) 2025-06-02
AU2022251843A1 (en) 2023-10-05
LT4313058T (lt) 2025-05-26
US20240058351A1 (en) 2024-02-22
RS66754B1 (sr) 2025-05-30
WO2022207646A1 (en) 2022-10-06
JP2024518685A (ja) 2024-05-02
US12605389B2 (en) 2026-04-21
PL4313058T3 (pl) 2025-06-23
AU2022251843B2 (en) 2026-04-09
HUE071610T2 (hu) 2025-09-28
EP4313058A1 (en) 2024-02-07
ES3031295T3 (en) 2025-07-07
CA3212731A1 (en) 2022-10-06
SI4313058T1 (sl) 2025-07-31
EP4313058B1 (en) 2025-03-05
FI4313058T3 (fi) 2025-04-30
MX2023011442A (es) 2023-10-18
HRP20250516T1 (hr) 2025-06-20
DK4313058T3 (da) 2025-05-12

Similar Documents

Publication Publication Date Title
US20200368235A1 (en) Ibrutinib combination therapy
US9364476B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
AU2012333092B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
EP3695839A1 (en) Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
KR20190033526A (ko) 병용 요법
JP7839803B2 (ja) 治療レジメンで使用するためのｐｉ３ｋ－デルタ阻害剤
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
EP3007693A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
US20140140991A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
EP4648766A1 (en) Pi3k inhibitors and methods of making and using the same
CN117042778A (zh) 用于治疗方案的PI3K-δ抑制剂
WO2010009332A1 (en) Binding and inhibiting 5-ht4 receptor
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
KR20160133005A (ko) 암 치료법의 조합
CN117083283A (zh) 用于癌症治疗的联合疗法
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
WO2014193589A1 (en) Cancer treatment method

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260323

R150 Certificate of patent or registration of utility model

Ref document number: 7839803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150